Skip to main content
. 2023 Nov 21;56(4):1281–1288. doi: 10.1007/s11255-023-03872-y

Table 2.

Baseline criteria of the two groups after PSM

Group A Group B P value
Patients, n 146 146
Genderb
 Male 96 (65.8%) 101 (69.2%) 0.625
 Female 50 (34.2%) 45 (30.8%)
Age median (min–max)d 53 (21–80) 52 (21–79) 0.895
BMI (kg/m2)c 24.7 ± 2.5 24.8 ± 2.3 0.875
Symptom
 Lumbagoe 100 (68.5%) 103 (70.5%) 0.795
 Symptomlesse 40 (27.4%) 37 (25.3%) 0.787
 Pyrexiae 14 (9.6%) 15 (10.3%) 1.000
 Vomitinge 28 (19.2%) 27 (18.5%) 1.000
 Hematuriae 17 (11.6%) 17 (11.6%) 1.000
Treatment history
 ESWLe 10 (6.8%) 11 (7.5%) 1.000
 Ureteroscopic lithotripsye 11 (7.5%) 11 (7.5%) 1.000
 Percutaneous nephrolithotomye 12 (8.2%) 14 (9.6%) 0.824
Past history
 Hypertensione 42 (28.8%) 41 (28.1%) 0.889
 Diabetese 13 (8.9%) 13 (8.9%) 1.000
Degree of hydronephrosise
 No 39 (26.7%) 40 (27.4%) 0.911
 Mild 53 (36.3%) 52 (35.6%)
 Moderate 46 (31.5%) 44 (30.1%)
 Severe 8 (5.48%) 10 (6.8%)
Urinary leucocytee
 No 37 (25.3%) 33 (22.6%) 0.555
 Possible 32 (21.9%) 35 (24.0%)
 Yes 77 (52.8%) 78 (53.4%)
Urinary nitritee 13 (8.9%) 12 (8.2%) 1.000
Urine culturee 21 (14.4%) 23 (15.8%) 0.864
 E. coli 10 11
 Enterococcus 4 3
 Proteus mirabilis 2 3
 Other 5 6
Stone size (mm)d 23.9 ± 9.0 24.3 ± 7.1 0.462
Operation sitee
 Left 74 (50.7%) 77 (52.7%) 0.810
 Right 72 (49.3%) 69 (47.3%)
Stone location
 Ureteric stonee 23 (15.8%) 22 (15.1%) 0.749
 Renal and ureteric stonee 26 (17.8%) 25 (17.1%) 1.000
 Renal stonee 84 (57.5%) 85 (58.2%) 1.000
 Staghorn stonee 13 (8.9%) 14 (9.6%) 1.000

cNormally distributed variable data analysed with paired-sample t test

dNonnormally distributed variable data analysed with the Wilcoxon-Mann–Whitney test

eCategorical variable data analysed with the McNemar test